However, we found that miR-302b, through the negative regulation of E2F1, targets ATM and we could confirm that miR-302b replacement therapy might enhance sensitivity to chemotherapy in breast cancer cells, targeting genes involved in mechanisms such as cell cycle and DDR frequently altered in cancer. Here, E2F1 is linked to breast cancer.